Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 17Recruiting 10Completed 8Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1

Interventions

pembrolizumab 4Radiotherapy 4Radiation 4ALT-803 4fludarabine 3Prednisone 3Etoposide 3Cytarabine 3Cyclophosphamide 3Cisplatin 3Biopsy 3sacituzumab govitecan 2daratumumab 2atezolizumab 2Vincristine 2Temozolomide 2Surveys and Questionnaires 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Irinotecan 2Gemcitabine 2Doxorubicin 2Blood Specimen Collection 2Bevacizumab 2Androgen Antagonists 2130-nm albumin-bound paclitaxel 2zimberelimab 1vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × niraparib × 90 days × Clear all
NCT06392841 2026-04-08

HARMONY

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡